(MedPage Today) — ORLANDO — Adding the bispecific antibody epcoritamab (Epkinly) to a standard chemotherapy-free regimen for relapsed or refractory follicular lymphoma improved responses and reduced the risk of disease progression or death…
Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118878
Author :
Publish date : 2025-12-07 21:18:00
Copyright for syndicated content belongs to the linked Source.
